There are 295 high confidence (HC) neoantigens in dbPepNeo, which are the most promising vaccine candidates because they have been validated to induce cytotoxic CD8+ T cell responses experimentally. Peptides can be usually validated by the reactivity of T cells in peripheral lymphocytes or autologous tumor infiltrating lymphocytes using ELISPOT or flow cytometry method of tetramer staining. The cancer type contained are as follows: melanoma, pancreatic cancer, non-small cell lung cancer, colorectal cancer, breast cancer, ovarian cancer, chronic lymphocytic leukemia, acute myeloid leukemia, esophageal cancer, neuroblastoma, multiple myeloma, squamous cell carcinoma, renal cell carcinoma and diffuse intrinsic pontine glioma.